|
US2809194A
(en)
*
|
|
1957-10-08 |
|
Thiadiazine type natriuretic agents |
|
US3108097A
(en)
*
|
|
1963-10-22 |
|
Ehnojs |
|
FR1103113A
(fr)
|
1954-04-15 |
1955-10-31 |
|
Triméthylol-alcanes et leur procédé de préparation
|
|
FR1217929A
(fr)
|
1958-03-03 |
1960-05-06 |
Ciba Geigy |
Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
|
|
BE578515A
(sh)
*
|
1958-05-07 |
|
|
|
|
DE1302648B
(sh)
|
1960-09-27 |
|
|
|
|
NL127065C
(sh)
*
|
1964-04-22 |
|
|
|
|
NL137318C
(sh)
*
|
1964-06-09 |
|
|
|
|
GB1415295A
(en)
|
1971-10-14 |
1975-11-26 |
Orchimed Sa |
Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
|
|
FI52570C
(fi)
*
|
1969-04-16 |
1977-10-10 |
Sumitomo Chemical Co |
Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
|
|
US3692895A
(en)
*
|
1970-09-08 |
1972-09-19 |
Norman A Nelson |
Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
|
|
DE2230383C3
(de)
*
|
1971-10-01 |
1981-12-03 |
Boehringer Mannheim Gmbh, 6800 Mannheim |
Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
|
|
US4148923A
(en)
*
|
1972-05-31 |
1979-04-10 |
Synthelabo |
1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
|
|
US3948973A
(en)
*
|
1972-08-29 |
1976-04-06 |
Sterling Drug Inc. |
Halocyclopropyl substituted phenoxyalkanoic acids
|
|
US4626549A
(en)
*
|
1974-01-10 |
1986-12-02 |
Eli Lilly And Company |
Treatment of obesity with aryloxyphenylpropylamines
|
|
US4235896A
(en)
*
|
1975-02-12 |
1980-11-25 |
Orchimed S.A. |
Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
|
|
US4179515A
(en)
*
|
1975-02-12 |
1979-12-18 |
Orchimed S. A. |
Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
|
|
JPS5195049A
(en)
*
|
1975-02-12 |
1976-08-20 |
|
* **********so*****no***tsu*****************************************ni*no
|
|
US4075000A
(en)
*
|
1975-05-27 |
1978-02-21 |
Eli Lilly And Company |
Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
|
|
US4576753A
(en)
*
|
1975-10-06 |
1986-03-18 |
Fujisawa Pharmaceutical Co., Ltd. |
Azetidinone compounds and processes for preparation thereof
|
|
US4472309A
(en)
*
|
1975-10-06 |
1984-09-18 |
Fujisawa Pharmaceutical Co., Ltd. |
2-Azetidinone compounds and processes for preparation thereof
|
|
US4304718A
(en)
*
|
1975-10-06 |
1981-12-08 |
Fujisawa Pharmaceutical Co., Ltd. |
2-Azetidinone compounds and processes for preparation thereof
|
|
US4166907A
(en)
*
|
1976-11-01 |
1979-09-04 |
E. R. Squibb & Sons, Inc. |
3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
|
|
US4144232A
(en)
*
|
1976-12-23 |
1979-03-13 |
Eli Lilly And Company |
Substituted azetidin-2-one antibiotics
|
|
FR2403078A1
(fr)
*
|
1977-09-19 |
1979-04-13 |
Lafon Labor |
Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
|
|
IT1157365B
(it)
*
|
1977-10-24 |
1987-02-11 |
Sandoz Ag |
Medicamenti per trattare l'obesita' o ridurre il peso del corpo
|
|
FR2408577A1
(fr)
|
1977-11-14 |
1979-06-08 |
Devinter Sa |
Nouveau procede de synthese d'esters para chlorobenzoyl phenoxy isobutyriques
|
|
NZ191762A
(en)
|
1978-10-19 |
1982-09-14 |
Merck & Co Inc |
Hypocholesteremic composition containing cholesterol synthesis inhibitor and anion exchange resin
|
|
US4250191A
(en)
*
|
1978-11-30 |
1981-02-10 |
Edwards K David |
Preventing renal failure
|
|
US4375475A
(en)
*
|
1979-08-17 |
1983-03-01 |
Merck & Co., Inc. |
Substituted pyranone inhibitors of cholesterol synthesis
|
|
US4260743A
(en)
*
|
1979-12-31 |
1981-04-07 |
Gist-Brocades N.V. |
Preparation of β-lactams and intermediates therefor
|
|
US4444784A
(en)
*
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
|
ES8101585A1
(es)
|
1980-02-15 |
1980-12-16 |
Especialidades Farmaco Terape |
Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
|
|
FR2494112B1
(sh)
|
1980-11-19 |
1986-01-10 |
Laruelle Claude |
|
|
DE3107100A1
(de)
*
|
1981-02-20 |
1982-09-09 |
Schering Ag, 1000 Berlin Und 4619 Bergkamen |
Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
|
|
US4500456A
(en)
*
|
1981-03-09 |
1985-02-19 |
Eli Lilly And Company |
Preparation of 4-fluoroazetidinones using FClO3
|
|
US4784734A
(en)
*
|
1981-04-10 |
1988-11-15 |
Otsuka Kagaku Yakuhin Kabushiki Kaisha |
Azetidinone derivatives and process for the preparation of the same
|
|
US4602005A
(en)
*
|
1982-05-17 |
1986-07-22 |
Medical Research Foundation Of Oregon |
Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
|
|
US4602003A
(en)
*
|
1982-05-17 |
1986-07-22 |
Medical Research Foundation Of Oregon |
Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
|
|
US4443372A
(en)
*
|
1982-06-23 |
1984-04-17 |
Chevron Research Company |
1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
|
|
US4534786A
(en)
*
|
1982-06-23 |
1985-08-13 |
Chevron Research Company |
1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
|
|
US4595532A
(en)
*
|
1983-02-02 |
1986-06-17 |
University Of Notre Dame Du Lac |
N-(substituted-methyl)-azetidin-2-ones
|
|
CA1256650A
(en)
*
|
1983-03-25 |
1989-06-27 |
Toshinari Tamura |
Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
|
|
US4614614A
(en)
*
|
1983-03-28 |
1986-09-30 |
Ciba-Geigy Corporation |
Process for the manufacture of optically active azetidinones
|
|
US4675399A
(en)
*
|
1983-03-28 |
1987-06-23 |
Notre Dame University |
Cyclization process for β-lactams
|
|
WO1985004876A1
(fr)
*
|
1984-04-24 |
1985-11-07 |
Takeda Chemical Industries, Ltd. |
Derives de 2-azetidinone et leur procede de preparation
|
|
US4576749A
(en)
*
|
1983-10-03 |
1986-03-18 |
E. R. Squibb & Sons, Inc. |
3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
|
|
US4680391A
(en)
|
1983-12-01 |
1987-07-14 |
Merck & Co., Inc. |
Substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US5229510A
(en)
*
|
1983-12-01 |
1993-07-20 |
Merck & Co., Inc. |
β-lactams useful in determining the amount of elastase in a clinical sample
|
|
US5229381A
(en)
*
|
1983-12-01 |
1993-07-20 |
Merck & Co., Inc. |
Substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US4654362A
(en)
*
|
1983-12-05 |
1987-03-31 |
Janssen Pharmaceutica, N.V. |
Derivatives of 2,2'-iminobisethanol
|
|
FR2561916B1
(fr)
*
|
1984-03-30 |
1987-12-11 |
Lafon Labor |
Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
|
|
US4633017A
(en)
*
|
1984-08-03 |
1986-12-30 |
E. R. Squibb & Sons, Inc. |
N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
|
|
US4581170A
(en)
*
|
1984-08-03 |
1986-04-08 |
E. R. Squibb & Sons, Inc. |
N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
|
|
US4576748A
(en)
*
|
1984-09-17 |
1986-03-18 |
Merck & Co., Inc. |
3-Hydroxy-3-aminoethyl β-lactams
|
|
US4647576A
(en)
|
1984-09-24 |
1987-03-03 |
Warner-Lambert Company |
Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
|
|
US4620867A
(en)
*
|
1984-09-28 |
1986-11-04 |
Chevron Research Company |
1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
|
|
AR240698A1
(es)
*
|
1985-01-19 |
1990-09-28 |
Takeda Chemical Industries Ltd |
Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
|
|
US4642903A
(en)
*
|
1985-03-26 |
1987-02-17 |
R. P. Scherer Corporation |
Freeze-dried foam dosage form
|
|
US4680289A
(en)
*
|
1985-06-05 |
1987-07-14 |
Progenics, Inc. |
Treatment of obesity and diabetes using sapogenins
|
|
JPH0679559B2
(ja)
|
1985-06-06 |
1994-10-12 |
三共株式会社 |
光学活性アゼチジノン誘導体の製法
|
|
EP0282492A1
(en)
|
1986-01-23 |
1988-09-21 |
The Upjohn Company |
Antimicrobial n-acyl-2-azetidinones
|
|
EP0234484B1
(en)
*
|
1986-02-19 |
1993-10-20 |
Sanraku Incorporated |
Novel azetidinone derivatives
|
|
GB8607312D0
(en)
*
|
1986-03-25 |
1986-04-30 |
Ici Plc |
Therapeutic agents
|
|
FR2598146B1
(fr)
*
|
1986-04-30 |
1989-01-20 |
Rech Ind |
Nouveau procede de preparation de fibrates.
|
|
DE3621861A1
(de)
*
|
1986-06-30 |
1988-01-14 |
Laszlo Dr Med Ilg |
Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
|
|
JPS6317859A
(ja)
|
1986-07-11 |
1988-01-25 |
Sagami Chem Res Center |
フルオロアゼチジノン誘導体
|
|
FR2602423B1
(fr)
*
|
1986-08-08 |
1989-05-05 |
Ethypharm Sa |
Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
|
|
US4814354A
(en)
*
|
1986-09-26 |
1989-03-21 |
Warner-Lambert Company |
Lipid regulating agents
|
|
IL84051A0
(en)
|
1986-10-03 |
1988-03-31 |
Lilly Co Eli |
7-((meta-substituted)phenylglycine)1-carba-1-dethiacephalosporins
|
|
US4803266A
(en)
*
|
1986-10-17 |
1989-02-07 |
Taisho Pharmaceutical Co., Ltd. |
3-Oxoalkylidene-2-azetidinone derivatives
|
|
PH25145A
(en)
|
1986-12-15 |
1991-02-19 |
Laverne Dwaine Boeck |
Process for producing the a10255 complex and corresponding microorganism
|
|
DE3781878T2
(de)
|
1986-12-15 |
1993-03-11 |
Lilly Co Eli |
Antibiotikum-a10255-komplex und faktoren, verfahren, mikroorganismen fuer seine herstellung.
|
|
US5229362A
(en)
*
|
1986-12-15 |
1993-07-20 |
Eli Lilly And Company |
Antibiotic A10255 complex and factors, and process and production therefor
|
|
JPS63156788A
(ja)
|
1986-12-22 |
1988-06-29 |
Sanraku Inc |
光学活性アゼチジノン類
|
|
AU1422388A
(en)
|
1987-01-27 |
1988-08-10 |
Warner-Lambert Company |
Lipid regulating compositions
|
|
US5110730A
(en)
*
|
1987-03-31 |
1992-05-05 |
The Scripps Research Institute |
Human tissue factor related DNA segments
|
|
EP0288973B1
(en)
|
1987-04-28 |
1993-01-13 |
Fujisawa Astra Ltd. |
Benzothiazolinone derivatives, their production and pharmaceutical composition
|
|
US5106833A
(en)
*
|
1987-07-23 |
1992-04-21 |
Washington University |
Coagulation inhibitors
|
|
EG18529A
(en)
|
1987-10-06 |
1993-04-30 |
Lilly Co Eli |
Process for preparing b-lactam hydrate
|
|
US5091525A
(en)
*
|
1987-10-07 |
1992-02-25 |
Eli Lilly And Company |
Monohydrate and DMF solvates of a new carbacephem antibiotic
|
|
US4834846A
(en)
*
|
1987-12-07 |
1989-05-30 |
Merck & Co., Inc. |
Process for deblocking N-substituted β-lactams
|
|
US5385885A
(en)
|
1988-01-15 |
1995-01-31 |
Gasic; Gregory P. |
Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
|
|
FR2627696B1
(fr)
*
|
1988-02-26 |
1991-09-13 |
Fournier Innovation Synergie |
Nouvelle forme galenique du fenofibrate
|
|
DE3807895A1
(de)
*
|
1988-03-10 |
1989-09-21 |
Knoll Ag |
Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
|
|
EP0333268A1
(en)
|
1988-03-18 |
1989-09-20 |
Merck & Co. Inc. |
Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
|
|
NZ228600A
(en)
|
1988-04-11 |
1992-02-25 |
Merck & Co Inc |
1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
|
|
GB8813012D0
(en)
*
|
1988-06-02 |
1988-07-06 |
Norsk Hydro As |
Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
|
|
FR2634376B1
(fr)
|
1988-07-21 |
1992-04-17 |
Farmalyoc |
Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
|
|
US4952689A
(en)
|
1988-10-20 |
1990-08-28 |
Taisho Pharmaceutical Co., Ltd. |
3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
|
|
CA2002596A1
(en)
|
1988-11-14 |
1990-05-14 |
Thomas M. Eckrich |
Hydrates of b-lactam antibiotic
|
|
CA1340977C
(en)
|
1988-11-15 |
2000-04-25 |
Monty Krieger |
Scavenger receptor protein and antibody thereto
|
|
US5112616A
(en)
*
|
1988-11-30 |
1992-05-12 |
Schering Corporation |
Fast dissolving buccal tablet
|
|
US5073374A
(en)
*
|
1988-11-30 |
1991-12-17 |
Schering Corporation |
Fast dissolving buccal tablet
|
|
US4876365A
(en)
*
|
1988-12-05 |
1989-10-24 |
Schering Corporation |
Intermediate compounds for preparing penems and carbapenems
|
|
US5260305A
(en)
*
|
1988-12-12 |
1993-11-09 |
E. R. Squibb & Sons, Inc. |
Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
|
|
FR2640621B1
(fr)
|
1988-12-19 |
1992-10-30 |
Centre Nat Rech Scient |
N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
|
|
US4990535A
(en)
*
|
1989-05-03 |
1991-02-05 |
Schering Corporation |
Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
|
|
US5033334A
(en)
*
|
1989-05-12 |
1991-07-23 |
Cornelius Phaal |
Wire drawing die
|
|
CA2016467A1
(en)
|
1989-06-05 |
1990-12-05 |
Martin Eisman |
Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
|
|
JPH03108490A
(ja)
*
|
1989-06-30 |
1991-05-08 |
Shionogi & Co Ltd |
フォスフォリパーゼａ↓２阻害物質
|
|
US5021461A
(en)
*
|
1989-07-26 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Method of treating diabetes mellitus with bisphenol derivatives
|
|
US4983597A
(en)
*
|
1989-08-31 |
1991-01-08 |
Merck & Co., Inc. |
Beta-lactams as anticholesterolemic agents
|
|
IL95574A
(en)
|
1989-09-09 |
1994-11-11 |
Knoll Ag |
Colestyramine preparation
|
|
US5219574A
(en)
|
1989-09-15 |
1993-06-15 |
Cima Labs. Inc. |
Magnesium carbonate and oil tableting aid and flavoring additive
|
|
US5178878A
(en)
*
|
1989-10-02 |
1993-01-12 |
Cima Labs, Inc. |
Effervescent dosage form with microparticles
|
|
US5223264A
(en)
*
|
1989-10-02 |
1993-06-29 |
Cima Labs, Inc. |
Pediatric effervescent dosage form
|
|
US5188825A
(en)
*
|
1989-12-28 |
1993-02-23 |
Iles Martin C |
Freeze-dried dosage forms and methods for preparing the same
|
|
CA2078217C
(en)
*
|
1990-04-13 |
2000-02-22 |
Dennis M. Godek |
Process for sultamicillin intermediate
|
|
CA2039763A1
(en)
|
1990-04-30 |
1991-10-31 |
Henry Y. Pan |
Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
|
|
CA2040865C
(en)
|
1990-05-15 |
2002-07-23 |
James L. Bergey |
Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
|
|
US5298497A
(en)
|
1990-05-15 |
1994-03-29 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of hypertension employing a cholesterol lowering drug
|
|
US5622985A
(en)
|
1990-06-11 |
1997-04-22 |
Bristol-Myers Squibb Company |
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
|
|
CA2042526A1
(en)
|
1990-06-11 |
1991-12-12 |
Adeoye Y. Olukotun |
Method for preventing a second heart attack employing an hmg coa reductase inhibitor
|
|
US5120729A
(en)
|
1990-06-20 |
1992-06-09 |
Merck & Co., Inc. |
Beta-lactams as antihypercholesterolemics
|
|
CA2048395A1
(en)
|
1990-08-23 |
1992-02-24 |
Henry Y. Pan |
Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
|
|
US5120713A
(en)
*
|
1990-09-10 |
1992-06-09 |
Applied Research Systems Ars Holding N.V. |
Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
|
|
US5075313A
(en)
|
1990-09-13 |
1991-12-24 |
Eli Lilly And Company |
3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
|
|
IL99658A0
(en)
|
1990-10-15 |
1992-08-18 |
Merck & Co Inc |
Substituted azetidinones and pharmaceutical compositions containing them
|
|
CA2052014A1
(en)
|
1990-10-19 |
1992-04-20 |
Henry Y. Pan |
Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
|
|
US5190970A
(en)
*
|
1990-10-19 |
1993-03-02 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
|
|
US5130333A
(en)
*
|
1990-10-19 |
1992-07-14 |
E. R. Squibb & Sons, Inc. |
Method for treating type II diabetes employing a cholesterol lowering drug
|
|
JP2640986B2
(ja)
*
|
1990-11-08 |
1997-08-13 |
高砂香料工業株式会社 |
（１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法
|
|
IL100091A
(en)
|
1990-12-12 |
1998-08-16 |
Zeneca Ltd |
Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
|
|
US5552160A
(en)
|
1991-01-25 |
1996-09-03 |
Nanosystems L.L.C. |
Surface modified NSAID nanoparticles
|
|
US5399363A
(en)
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
|
US5145684A
(en)
*
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
AU642066B2
(en)
|
1991-01-25 |
1993-10-07 |
Nanosystems L.L.C. |
X-ray contrast compositions useful in medical imaging
|
|
IT1244699B
(it)
|
1991-02-01 |
1994-08-08 |
Luso Farmaco Inst |
Processo per la preparazione di acidi 3 acilammino-4- carbamoilossimetil-2-azetidinone-l-solfonici ed intermedi per la loro preparazione
|
|
US5157025A
(en)
*
|
1991-04-01 |
1992-10-20 |
E. R. Squibb & Sons, Inc. |
Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
|
|
US5348953A
(en)
|
1991-06-25 |
1994-09-20 |
Merck & Co., Inc. |
Substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US5464632C1
(en)
|
1991-07-22 |
2001-02-20 |
Prographarm Lab |
Rapidly disintegratable multiparticular tablet
|
|
US5561227A
(en)
|
1991-07-23 |
1996-10-01 |
Schering Corporation |
Process for the stereospecific synthesis of azetidinones
|
|
US5688785A
(en)
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
ATE158789T1
(de)
|
1991-07-23 |
1997-10-15 |
Schering Corp |
Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung
|
|
US5688787A
(en)
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
|
|
JP2620437B2
(ja)
|
1991-09-27 |
1997-06-11 |
宇部興産株式会社 |
ω−ヒドロキシ−（ω−３）−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法
|
|
WO1993007167A1
(en)
|
1991-10-04 |
1993-04-15 |
The Procter & Gamble Company |
Cholesterol lowering compounds and process for making them
|
|
US5162117A
(en)
*
|
1991-11-22 |
1992-11-10 |
Schering Corporation |
Controlled release flutamide composition
|
|
CA2123684A1
(en)
|
1991-11-25 |
1993-06-10 |
Douglas J. M. Allen |
Method for making steroidal peracyl glycosides
|
|
DE4203932A1
(de)
|
1992-02-11 |
1993-08-12 |
Deutsche Aerospace |
Sende-/empfangsmodul
|
|
US6063764A
(en)
|
1992-06-01 |
2000-05-16 |
Washington University & Chiron Corp. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
|
BR9306619A
(pt)
|
1992-06-26 |
1998-12-08 |
Pfizer |
Glicosídeos esteroidais para o tratamento da hipercolesterolemia
|
|
US5278176A
(en)
*
|
1992-08-21 |
1994-01-11 |
Abbott Laboratories |
Nicotine derivatives that enhance cognitive function
|
|
EP0666846A1
(en)
|
1992-10-27 |
1995-08-16 |
Merck & Co. Inc. |
New substituted azetidinones as anti-inflammatory and antidegenerative agents
|
|
US5631363A
(en)
|
1992-11-13 |
1997-05-20 |
Tanabe Seiyaku Co., Ltd. |
Azetidinone compound and process for preparation thereof
|
|
AU660852B2
(en)
|
1992-11-25 |
1995-07-06 |
Elan Pharma International Limited |
Method of grinding pharmaceutical substances
|
|
WO1994020535A1
(en)
|
1992-12-11 |
1994-09-15 |
Corvas International, Inc. |
ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
|
|
US5429824A
(en)
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
|
US5358852A
(en)
|
1992-12-21 |
1994-10-25 |
Eastman Kodak Company |
Use of calcium in immunoassay for measurement of C-reactive protein
|
|
LT3300B
(en)
|
1992-12-23 |
1995-06-26 |
Schering Corp |
Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
|
|
LT3595B
(en)
|
1993-01-21 |
1995-12-27 |
Schering Corp |
Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
|
|
US5563264A
(en)
|
1993-02-10 |
1996-10-08 |
Shionogi & Co., Ltd. |
Preparation of βlactam compounds
|
|
US5503846A
(en)
|
1993-03-17 |
1996-04-02 |
Cima Labs, Inc. |
Base coated acid particles and effervescent formulation incorporating same
|
|
US5412092A
(en)
|
1993-04-23 |
1995-05-02 |
Bristol-Myers Squibb Company |
N-substituted 2-azetidinones
|
|
IL109568A0
(en)
|
1993-05-19 |
1994-08-26 |
Fujisawa Pharmaceutical Co |
Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
|
|
US5703188A
(en)
|
1993-06-02 |
1997-12-30 |
Geltex Pharmaceuticals, Inc. |
Process for removing bile salts from a patient and compositions therefor
|
|
US5550229A
(en)
|
1993-06-23 |
1996-08-27 |
Tanabe Seiyaku Co., Ltd. |
Alkylation process for preparing azetidinone compound and starting compound therefor
|
|
WO1995001961A1
(en)
|
1993-07-09 |
1995-01-19 |
Schering Corporation |
Process for the synthesis of azetidinones
|
|
WO1995001782A2
(en)
|
1993-07-09 |
1995-01-19 |
R.P. Scherer Corporation |
Method for making freeze dried drug dosage forms
|
|
AU7376494A
(en)
|
1993-08-04 |
1995-02-28 |
Andrulis Pharmaceuticals Corporation |
Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
|
|
AU7397094A
(en)
|
1993-08-30 |
1995-03-22 |
Merck & Co., Inc. |
Prevention and treatment of alzheimer's disease
|
|
US5851553A
(en)
|
1993-09-10 |
1998-12-22 |
Fuisz Technologies, Ltd. |
Process and apparatus for making rapidly dissolving dosage units and product therefrom
|
|
US5622719A
(en)
|
1993-09-10 |
1997-04-22 |
Fuisz Technologies Ltd. |
Process and apparatus for making rapidly dissolving dosage units and product therefrom
|
|
US5895664A
(en)
|
1993-09-10 |
1999-04-20 |
Fuisz Technologies Ltd. |
Process for forming quickly dispersing comestible unit and product therefrom
|
|
US5631365A
(en)
*
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5976570A
(en)
|
1993-12-21 |
1999-11-02 |
Applied Analytical Industries, Inc. |
Method for preparing low dose pharmaceutical products
|
|
EP0737202A1
(en)
|
1993-12-28 |
1996-10-16 |
Pfizer Inc. |
Hypocholesterolemic agents
|
|
US6369103B1
(en)
|
1994-01-18 |
2002-04-09 |
Bristol-Myers Squibb Company |
Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
|
|
US5595761A
(en)
|
1994-01-27 |
1997-01-21 |
The Board Of Regents Of The University Of Oklahoma |
Particulate support matrix for making a rapidly dissolving tablet
|
|
US5576014A
(en)
|
1994-01-31 |
1996-11-19 |
Yamanouchi Pharmaceutical Co., Ltd |
Intrabuccally dissolving compressed moldings and production process thereof
|
|
GB9401892D0
(en)
|
1994-02-01 |
1994-03-30 |
Boots Co Plc |
Therapeutic agents
|
|
US5635210A
(en)
|
1994-02-03 |
1997-06-03 |
The Board Of Regents Of The University Of Oklahoma |
Method of making a rapidly dissolving tablet
|
|
US5627176A
(en)
*
|
1994-03-25 |
1997-05-06 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
GB9406074D0
(en)
|
1994-03-26 |
1994-05-18 |
Glaxo Spa |
Chemical process
|
|
DE4414538A1
(de)
|
1994-04-26 |
1995-11-02 |
Klinge Co Chem Pharm Fab |
Präparate zur Therapie der kombinierten Hyperlipidämie mit einem Gehalt an einem p-Oxybenzoesäurederivat und einem Fibrat
|
|
US5554746A
(en)
|
1994-05-16 |
1996-09-10 |
Isis Pharmaceuticals, Inc. |
Lactam nucleic acids
|
|
TW384224B
(en)
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
|
US5718388A
(en)
|
1994-05-25 |
1998-02-17 |
Eastman Kodak |
Continuous method of grinding pharmaceutical substances
|
|
US5567439A
(en)
|
1994-06-14 |
1996-10-22 |
Fuisz Technologies Ltd. |
Delivery of controlled-release systems(s)
|
|
CA2191455A1
(en)
|
1994-06-20 |
1995-12-28 |
Wayne Vaccaro |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US6429289B1
(en)
|
1994-06-23 |
2002-08-06 |
Massachusetts Institute Of Technology |
Class BI and CI scavenger receptors
|
|
EP0782451A1
(en)
|
1994-09-20 |
1997-07-09 |
Pfizer Inc. |
Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
|
|
GB9421836D0
(en)
|
1994-10-28 |
1994-12-14 |
Scherer Corp R P |
Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
|
|
GB9421816D0
(en)
|
1994-10-29 |
1994-12-14 |
Smithkline Beecham Plc |
Novel compounds
|
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5633246A
(en)
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
|
AU704407B2
(en)
|
1994-12-22 |
1999-04-22 |
Smithkline Beecham Plc |
Substituted azetidin-2-ones for treatment of atherosclerosis
|
|
US5902726A
(en)
|
1994-12-23 |
1999-05-11 |
Glaxo Wellcome Inc. |
Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
|
|
CA2207333C
(en)
|
1994-12-28 |
2006-10-17 |
Janssen Pharmaceutica, Naamloze Vennootschap |
Use of nebivolol as an anti-atherogenic
|
|
US5545628A
(en)
|
1995-01-10 |
1996-08-13 |
Galephar P.R. Inc. |
Pharmaceutical composition containing fenofibrate
|
|
FR2730231B1
(fr)
|
1995-02-02 |
1997-04-04 |
Fournier Sca Lab |
Association de fenofibrate et de vitamine e, utilisation en therapeutique
|
|
US5639475A
(en)
|
1995-02-03 |
1997-06-17 |
Eurand America, Incorporated |
Effervescent microcapsules
|
|
US5518738A
(en)
|
1995-02-09 |
1996-05-21 |
Nanosystem L.L.C. |
Nanoparticulate nsaid compositions
|
|
US5591456A
(en)
|
1995-02-10 |
1997-01-07 |
Nanosystems L.L.C. |
Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
|
|
US5510118A
(en)
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
|
US5747001A
(en)
|
1995-02-24 |
1998-05-05 |
Nanosystems, L.L.C. |
Aerosols containing beclomethazone nanoparticle dispersions
|
|
US5998441A
(en)
|
1995-02-28 |
1999-12-07 |
Eli Lilly And Company |
Benzothiophene compounds, intermediates, compositions, and methods
|
|
US5639739A
(en)
|
1995-03-24 |
1997-06-17 |
The Dupont Merck Pharmaceutical Company |
Imidazole containing aminoboronic acids
|
|
US5759865A
(en)
|
1995-05-03 |
1998-06-02 |
Eli Lilly And Company |
Combinatorial process for synthesizing azetidinone analogs
|
|
DE19518988A1
(de)
|
1995-05-29 |
1996-12-05 |
Basf Ag |
Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
|
|
JP3144624B2
(ja)
*
|
1995-06-02 |
2001-03-12 |
杏林製薬株式会社 |
Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
|
|
US5612378A
(en)
|
1995-06-06 |
1997-03-18 |
3-Dimensional Pharmaceuticals, Inc. |
Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
|
|
US5607697A
(en)
|
1995-06-07 |
1997-03-04 |
Cima Labs, Incorporated |
Taste masking microparticles for oral dosage forms
|
|
US5612353A
(en)
|
1995-06-07 |
1997-03-18 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
|
|
AU6039296A
(en)
|
1995-06-07 |
1996-12-30 |
G.D. Searle & Co. |
Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
|
|
HUP9601808A3
(en)
|
1995-07-03 |
2000-06-28 |
Sankyo Co |
Treatment of arteriosclerosis and xanthoma
|
|
FR2737121B1
(fr)
|
1995-07-27 |
1997-10-03 |
Cl Pharma |
Nouvelles formulations galeniques du fenofibrate et leurs applications
|
|
US5698527A
(en)
|
1995-08-08 |
1997-12-16 |
Merck & Co., Inc. |
Steroidal glycosides as antihyperlipidemic agents
|
|
FR2738817B1
(fr)
|
1995-09-14 |
1997-10-17 |
Adir |
Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US5618707A
(en)
|
1996-01-04 |
1997-04-08 |
Schering Corporation |
Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
|
|
US5808056A
(en)
|
1995-10-31 |
1998-09-15 |
Merck & Co., Inc. |
Process for preparing substituted azetidinones
|
|
CZ293957B6
(cs)
*
|
1995-10-31 |
2004-08-18 |
Scheringácorporation |
@@Azetidinony substituované cukernými zbytkyŹ použitelné jako hypocholesterolemikaŹ farmaceutický prostředek a kit je obsahující
|
|
WO1997016424A1
(en)
|
1995-11-02 |
1997-05-09 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
|
JP2000500155A
(ja)
|
1995-11-14 |
2000-01-11 |
クノール ファーマスーティカル カンパニー |
安定化された甲状腺ホルモン製剤及びその製法
|
|
US5925333A
(en)
|
1995-11-15 |
1999-07-20 |
Massachusetts Institute Of Technology |
Methods for modulation of lipid uptake
|
|
JPH09143156A
(ja)
|
1995-11-17 |
1997-06-03 |
Tanabe Seiyaku Co Ltd |
アセトキシアゼチジノン誘導体の製法及びその合成中間体
|
|
US5807578A
(en)
|
1995-11-22 |
1998-09-15 |
Lab Pharmaceutical Research International Inc. |
Fast-melt tablet and method of making same
|
|
US5807577A
(en)
|
1995-11-22 |
1998-09-15 |
Lab Pharmaceutical Research International Inc. |
Fast-melt tablet and method of making same
|
|
JP2000505063A
(ja)
|
1995-12-08 |
2000-04-25 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
アテローム性動脈硬化症の治療のためのアゼチジノン化合物
|
|
US6080767A
(en)
|
1996-01-02 |
2000-06-27 |
Aventis Pharmaceuticals Products Inc. |
Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
|
|
GB9600464D0
(en)
|
1996-01-09 |
1996-03-13 |
Smithkline Beecham Plc |
Novel method
|
|
US5859051A
(en)
|
1996-02-02 |
1999-01-12 |
Merck & Co., Inc. |
Antidiabetic agents
|
|
WO1997028149A1
(en)
|
1996-02-02 |
1997-08-07 |
Merck & Co., Inc. |
Method for raising hdl cholesterol levels
|
|
US5847008A
(en)
|
1996-02-02 |
1998-12-08 |
Merck & Co., Inc. |
Method of treating diabetes and related disease states
|
|
GB9604242D0
(en)
|
1996-02-28 |
1996-05-01 |
Glaxo Wellcome Inc |
Chemical compounds
|
|
DE19608750A1
(de)
|
1996-03-06 |
1997-09-11 |
Durachemie Gmbh & Co Kg |
Verfahren zur Herstellung von Fenofibrat-Präparaten
|
|
IL117702A0
(en)
|
1996-03-28 |
1996-07-23 |
Tel Aviv Medical Center Resear |
Drug for hyperlipoproteinemia
|
|
GB9606805D0
(en)
|
1996-03-30 |
1996-06-05 |
Glaxo Wellcome Inc |
Medicaments
|
|
US5858409A
(en)
|
1996-04-17 |
1999-01-12 |
Fmc Corporation |
Hydrolyzed cellulose granulations for pharmaceuticals
|
|
IL126696A0
(en)
|
1996-04-26 |
1999-08-17 |
Smithkline Beecham Plc |
Azetidinone derivatives for the treatment of atherosclerosis
|
|
US5843984A
(en)
|
1996-05-09 |
1998-12-01 |
Eli Lilly And Company |
Sulfated benzothiophene derivatives, methods of use and formulations containing same
|
|
US5886171A
(en)
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
|
US5739321A
(en)
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
|
US6245743B1
(en)
|
1996-06-05 |
2001-06-12 |
Cor Therapeutics, Inc. |
Inhibitors of factor Xa
|
|
GB9611947D0
(en)
|
1996-06-07 |
1996-08-07 |
Glaxo Group Ltd |
Medicaments
|
|
TW464495B
(en)
|
1996-06-12 |
2001-11-21 |
Kyowa Hakko Kogyo Kk |
Lipid metabolic ameliorative agent
|
|
US5965553A
(en)
|
1996-06-20 |
1999-10-12 |
Pfizer Inc. |
Squalene synthetase inhibitors
|
|
AU4326197A
(en)
|
1996-07-09 |
1998-02-02 |
Merck & Co., Inc. |
Pharmaceutical compositions
|
|
US6139873A
(en)
|
1996-07-10 |
2000-10-31 |
Cedars-Sinai Medical Center |
Combined pharmaceutical estrogen-androgen-progestin
|
|
US5883109A
(en)
|
1996-07-24 |
1999-03-16 |
Bristol-Myers Squibb Company |
Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
|
|
US5952003A
(en)
|
1996-08-01 |
1999-09-14 |
Novartis Corporation |
Terazosin capsules
|
|
WO1998005331A2
(en)
|
1996-08-02 |
1998-02-12 |
Ligand Pharmaceuticals Incorporated |
Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
|
|
US6057342A
(en)
|
1996-08-16 |
2000-05-02 |
Dupont Pharmaceutical Co. |
Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
|
|
US6235706B1
(en)
|
1996-09-18 |
2001-05-22 |
Merck & Co., Inc. |
Combination therapy for reducing the risks associated with cardiovascular disease
|
|
US6251852B1
(en)
|
1996-09-18 |
2001-06-26 |
Merck & Co., Inc. |
Combination therapy for reducing the risks associated with cardiovascular disease
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
US5959123A
(en)
|
1996-09-23 |
1999-09-28 |
Synphar Laboratories, Inc. |
3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
|
|
HUP0000116A3
(en)
|
1996-10-01 |
2000-08-28 |
Stanford Res Inst Int |
Taste-masked microcapsule compositions and methods of manufacture
|
|
US6262047B1
(en)
|
1996-10-11 |
2001-07-17 |
Cor Therapeutics, Inc. |
Selective factor Xa inhibitors
|
|
US5756470A
(en)
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
CA2272317C
(en)
|
1996-11-27 |
2001-01-30 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound
|
|
US6090839A
(en)
|
1996-12-23 |
2000-07-18 |
Merck & Co., Inc. |
Antidiabetic agents
|
|
FR2758459B1
(fr)
|
1997-01-17 |
1999-05-07 |
Pharma Pass |
Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
|
|
JP2001508795A
(ja)
|
1997-01-17 |
2001-07-03 |
ブリストル−マイヤーズ・スクイブ・カンパニー |
Ｍｔｐインヒビター単独またはこれと他のコレステロール降下薬を組合せて用いる心臓血管疾患の発病の危険を予防または軽減する方法
|
|
US6066653A
(en)
|
1997-01-17 |
2000-05-23 |
Bristol-Myers Squibb Co. |
Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
|
|
FR2758461A1
(fr)
|
1997-01-17 |
1998-07-24 |
Pharma Pass |
Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
|
|
AU6773598A
(en)
|
1997-03-26 |
1998-10-20 |
Institut Pasteur |
Treatment of gastrointestinal disease with ppar modulators
|
|
WO1998043630A1
(en)
|
1997-04-02 |
1998-10-08 |
Brigham And Women's Hospital, Inc. |
Means of ascertaining an individual's risk profile for atherosclerotic disease
|
|
US6024981A
(en)
|
1997-04-16 |
2000-02-15 |
Cima Labs Inc. |
Rapidly dissolving robust dosage form
|
|
DE19716120A1
(de)
|
1997-04-17 |
1998-10-22 |
Europ Lab Molekularbiolog |
Verwendung von cholesterinsenkenden Mitteln
|
|
CA2287397A1
(en)
|
1997-04-24 |
1998-10-29 |
Merck Sharp & Dohme Limited |
Use of an nk-1 receptor antagonist and an ssri for treating obesity
|
|
CN1275596C
(zh)
|
1997-05-14 |
2006-09-20 |
阿特罗吉尼克斯公司 |
普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用
|
|
AU8257898A
(en)
*
|
1997-06-17 |
1999-01-04 |
Rutgers, The State University Of New Jersey |
Hypocholesterolemic compositions from bamboo shoots
|
|
US6423754B1
(en)
|
1997-06-18 |
2002-07-23 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with polyallylamine polymers
|
|
US6300364B1
(en)
|
1997-07-24 |
2001-10-09 |
Yamanouchi Pharmaceutical Co., Ltd. |
Medicinal compositions with cholesterol-lowering effect
|
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
|
ATE451926T1
(de)
|
1997-07-31 |
2010-01-15 |
Abbott Respiratory Llc |
Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie
|
|
WO1999007381A1
(en)
|
1997-08-11 |
1999-02-18 |
Weider Nutrition International, Inc. |
Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
|
|
US5886191A
(en)
|
1997-08-18 |
1999-03-23 |
Dupont Pharmaceuticals Company |
Amidinoindoles, amidinoazoles, and analogs thereof
|
|
US5869098A
(en)
|
1997-08-20 |
1999-02-09 |
Fuisz Technologies Ltd. |
Fast-dissolving comestible units formed under high-speed/high-pressure conditions
|
|
EP1007019A2
(en)
|
1997-08-26 |
2000-06-14 |
Merck & Co., Inc. |
Cholesterol-lowering therapy
|
|
US6180660B1
(en)
|
1997-08-26 |
2001-01-30 |
Merck & Co., Inc. |
Cholesterol-lowering therapy
|
|
US6143885A
(en)
|
1997-08-27 |
2000-11-07 |
Merck & Co., Inc. |
Preparation of beta-methyl carbapenem intermediates
|
|
GT199800126A
(es)
|
1997-08-29 |
2000-01-29 |
|
Terapia de combinacion.
|
|
WO1999012903A1
(en)
|
1997-09-09 |
1999-03-18 |
Du Pont Pharmaceuticals Company |
Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
|
|
WO1999012534A1
(en)
|
1997-09-10 |
1999-03-18 |
Ono Pharmaceutical Co., Ltd. |
Peroxisome proliferator-activated receptor controllers
|
|
GB2329334A
(en)
|
1997-09-18 |
1999-03-24 |
Reckitt & Colmann Prod Ltd |
Cholesterol-lowering agents
|
|
CA2214895C
(en)
|
1997-09-19 |
1999-04-20 |
Bernard Charles Sherman |
Improved pharmaceutical composition comprising fenofibrate
|
|
AU9002798A
(en)
|
1997-09-19 |
1999-04-12 |
Ono Pharmaceutical Co. Ltd. |
Fused or nonfused benzene compounds
|
|
JP2001517617A
(ja)
|
1997-09-24 |
2001-10-09 |
ノヴァ モレキュラー インク． |
神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
|
|
IE970731A1
(en)
|
1997-10-07 |
2000-10-04 |
Fuisz Internat Ltd |
Product and method for the treatment of hyperlipidemia
|
|
ATE224872T1
(de)
|
1997-10-07 |
2002-10-15 |
Boehringer Ingelheim Ca Ltd |
Azetidinonderivate zur behandlung von hcmv entzündungen
|
|
US6147109A
(en)
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
|
US6005102A
(en)
|
1997-10-15 |
1999-12-21 |
American Home Products Corporation |
Aryloxy-alkyl-dialkylamines
|
|
EA200000427A1
(ru)
|
1997-10-17 |
2001-02-26 |
Авентис Фармасьютикалз Продактс Инк. |
Терапевтические применения хинолиновых производных
|
|
US6576660B1
(en)
|
1997-10-31 |
2003-06-10 |
Arch Development Corporation |
Methods and compositions for regulation of 5-α-reductase activity
|
|
US20030153541A1
(en)
*
|
1997-10-31 |
2003-08-14 |
Robert Dudley |
Novel anticholesterol compositions and method for using same
|
|
US6027747A
(en)
|
1997-11-11 |
2000-02-22 |
Terracol; Didier |
Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
|
|
WO1999029300A1
(en)
|
1997-12-10 |
1999-06-17 |
Rtp Pharma Inc. |
Self-emulsifying fenofibrate formulations
|
|
US5985936A
(en)
|
1997-12-18 |
1999-11-16 |
Forbes Medi-Tech, Inc. |
Method of preventing and delaying onset of Alzheimer's disease and composition therefor
|
|
US6008237A
(en)
|
1997-12-19 |
1999-12-28 |
Merck & Co., Inc. |
Arylthiazolidinedione derivatives
|
|
NZ505761A
(en)
|
1998-01-28 |
2003-08-29 |
Warner Lambert Co |
Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis
|
|
ES2317688T3
(es)
|
1998-01-29 |
2009-04-16 |
Amgen Inc. |
Moduladores ppar-gamma.
|
|
WO1999038850A1
(en)
|
1998-01-29 |
1999-08-05 |
Dr. Reddy's Research Foundation |
Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
|
US6133001A
(en)
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
|
US6506757B1
(en)
|
1998-03-10 |
2003-01-14 |
Ono Pharmaceutical Co., Ltd. |
Carboxylic acid derivatives and drugs containing the same as the active ingredient
|
|
US6235311B1
(en)
|
1998-03-18 |
2001-05-22 |
Bristol-Myers Squibb Company |
Pharmaceutical composition containing a combination of a statin and aspirin and method
|
|
US6080778A
(en)
|
1998-03-23 |
2000-06-27 |
Children's Medical Center Corporation |
Methods for decreasing beta amyloid protein
|
|
US6180625B1
(en)
|
1998-03-24 |
2001-01-30 |
Novo Nordisk A/S |
Heterocyclic compounds regulating clotting
|
|
CA2321538A1
(en)
|
1998-03-27 |
1999-10-07 |
Dupont Pharmaceuticals Company |
Disubstituted pyrazolines and triazolines as factor xa inhibitors
|
|
AU3567299A
(en)
*
|
1998-04-17 |
1999-11-08 |
Medical Isotopes Inc. |
Phytosterol formulations to lower cholesterol absorption
|
|
WO1999008501A2
(en)
|
1998-04-23 |
1999-02-25 |
Dr. Reddy's Research Foundation |
New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
|
EP1076644B1
(en)
|
1998-04-29 |
2004-06-23 |
Ortho-McNeil Pharmaceutical, Inc. |
N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
|
|
EP1082313A1
(en)
|
1998-05-27 |
2001-03-14 |
Dr. Reddy's Research Foundation |
Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
|
|
US6262042B1
(en)
|
1998-05-29 |
2001-07-17 |
Research Triangle Institute |
17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
|
FR2779347A1
(fr)
|
1998-06-05 |
1999-12-03 |
Arlette Guerry |
Procede de micronisation de substances medicamenteuses
|
|
EP1089731A4
(en)
|
1998-06-24 |
2003-06-18 |
Merck & Co Inc |
COMPOSITIONS AND METHOD FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
|
|
CA2336192A1
(en)
|
1998-06-24 |
1999-12-29 |
Merck & Co., Inc. |
Compositions and methods for treating elevated blood cholesterol
|
|
US6099865A
(en)
|
1998-07-08 |
2000-08-08 |
Fmc Corporation |
Croscarmellose taste masking
|
|
FR2781222A1
(fr)
|
1998-07-17 |
2000-01-21 |
Lipha |
Composes cycliques utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procede de preparation
|
|
AU5027299A
(en)
|
1998-07-31 |
2000-02-28 |
Novo Nordisk A/S |
Use of glp-1 and analogues for preventing type ii diabetes
|
|
JP2002522425A
(ja)
|
1998-08-07 |
2002-07-23 |
カイロン コーポレイション |
エストロゲンレセプターモジュレーターとしての置換イソオキサゾール
|
|
FR2783421B1
(fr)
|
1998-09-17 |
2000-11-24 |
Cll Pharma |
Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
|
|
US6147090A
(en)
|
1998-09-17 |
2000-11-14 |
Pfizer Inc. |
4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
|
|
CZ20011035A3
(cs)
|
1998-09-30 |
2001-10-17 |
Warner-Lambert Company |
Léčivo pro prevenci nebo oddálení revaskularizace pomocí katetru u pacientů postiľených chorobou koronární artérie
|
|
US5919672A
(en)
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
|
JP2002527507A
(ja)
|
1998-10-21 |
2002-08-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規化合物類、それらの調製及び使用
|
|
AU6325699A
(en)
|
1998-10-21 |
2000-05-08 |
Dr. Reddy's Research Foundation |
New compounds, their preparation and use
|
|
AU6325599A
(en)
|
1998-10-21 |
2000-05-08 |
Dr. Reddy's Research Foundation |
New compounds, their preparation and use
|
|
US6353018B1
(en)
|
1998-10-21 |
2002-03-05 |
Novo Nordisk A/S |
Compounds, their preparation and use
|
|
AU6325799A
(en)
|
1998-10-21 |
2000-05-08 |
Dr. Reddy's Research Foundation |
New compounds, their preparation and use
|
|
US6248781B1
(en)
|
1998-10-21 |
2001-06-19 |
Novo Nordisk A/S |
Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
|
|
CA2253769C
(en)
|
1998-11-10 |
2000-09-26 |
Bernard Charles Sherman |
Pharmaceutical compositions comprising fenofibrate
|
|
US6472421B1
(en)
|
1998-11-13 |
2002-10-29 |
Nymox Corporation |
Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
|
|
EP1133699A1
(en)
|
1998-11-25 |
2001-09-19 |
Scios Inc. |
Prevention and treatment of amyloid-associated disorders
|
|
SA99191255B1
(ar)
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
|
CA2353981C
(en)
|
1998-12-07 |
2005-04-26 |
Schering Corporation |
Process for the synthesis of azetidinones
|
|
US6277584B1
(en)
|
1998-12-16 |
2001-08-21 |
Dade Behring Inc. |
Method for calibrating a chemical analyzer with improved accuracy at low signal levels
|
|
JP2002532539A
(ja)
|
1998-12-18 |
2002-10-02 |
アボット・ラボラトリーズ |
脂質調節剤を含む新規な製剤
|
|
DE19858789A1
(de)
|
1998-12-18 |
2000-06-21 |
Bayer Ag |
Kombination von Cerivastatin und Fibraten
|
|
CA2356157C
(en)
|
1998-12-23 |
2008-04-01 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
|
EA004877B1
(ru)
|
1998-12-23 |
2004-08-26 |
Джи.Ди.Сирл Ллс |
Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
|
|
EP1140185B1
(en)
|
1998-12-23 |
2003-06-04 |
G.D. Searle LLC. |
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
|
|
EP1354604A1
(en)
|
1998-12-23 |
2003-10-22 |
G.D. Searle LLC. |
Combinations for cardiovascular indications
|
|
AU776620B2
(en)
|
1998-12-23 |
2004-09-16 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
|
ES2188285T3
(es)
|
1998-12-23 |
2003-06-16 |
Searle Llc |
Combinaciones de inhibidores del transporte de acidos biliares ileales y derivados de acido nicotinico para indicaciones cardiovasculares.
|
|
ATE242007T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
|
|
ATE240120T1
(de)
|
1998-12-23 |
2003-05-15 |
Searle Llc |
Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
|
|
AR022204A1
(es)
|
1999-01-08 |
2002-09-04 |
Norgine Bv |
Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
|
|
US6180138B1
(en)
|
1999-01-29 |
2001-01-30 |
Abbott Laboratories |
Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
|
|
GB0000710D0
(en)
|
1999-02-06 |
2000-03-08 |
Zeneca Ltd |
Drug combination
|
|
AU2690600A
(en)
|
1999-02-24 |
2000-09-14 |
Fuji Chemical Industries, Ltd. |
2-mercaptocarboxylic acid derivatives
|
|
WO2000053173A1
(en)
|
1999-03-08 |
2000-09-14 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
|
|
EP1036563A1
(en)
|
1999-03-08 |
2000-09-20 |
MERCK & CO. INC. |
Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
|
|
JP2002538189A
(ja)
|
1999-03-10 |
2002-11-12 |
ジー．ディー．サール アンド カンパニー |
シクロオキシゲナーゼ−２インヒビターの投与方法と組成物
|
|
AU2943300A
(en)
|
1999-03-11 |
2000-09-28 |
Institute Of Research And Innovation |
Novel ligands of nuclear receptors ppar's
|
|
EP1175246A4
(en)
|
1999-03-19 |
2004-12-15 |
Brigham & Womens Hospital |
POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE OF TYPE III ENDOTHELIAL CELLS BY HMG-COA REDUCTASE INHIBITORS
|
|
EP1162954A1
(en)
|
1999-03-31 |
2001-12-19 |
Abbott Laboratories |
Novel formulations comprising lipid-regulating agents
|
|
MXPA01009839A
(es)
|
1999-03-31 |
2002-06-21 |
Abbott Lab |
Nuevas formulaciones que comprenden agentes reguladores de lipido.
|
|
CA2367289C
(en)
|
1999-04-05 |
2008-02-12 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
|
WO2000063703A1
(en)
|
1999-04-16 |
2000-10-26 |
Schering Corporation |
Use of azetidinone compounds
|
|
EP1173408B1
(en)
|
1999-04-19 |
2005-07-20 |
Coelacanth Corporation |
Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
|
|
WO2000063190A1
(en)
|
1999-04-20 |
2000-10-26 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
AU3958100A
(en)
|
1999-04-20 |
2000-11-02 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
HUP0200807A3
(en)
|
1999-04-20 |
2003-03-28 |
Novo Nordisk As |
Substituted propionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and their use
|
|
AU3958200A
(en)
|
1999-04-20 |
2000-11-02 |
Novo Nordisk A/S |
New compounds, their preparation and use
|
|
CA2270306C
(en)
|
1999-04-27 |
2000-09-26 |
Bernard Charles Sherman |
Pharmaceutical compositions comprising co-micronized fenofibrate
|
|
US6033656A
(en)
|
1999-05-04 |
2000-03-07 |
Sumitomo Chemical Company, Limited |
Method of preventing or alleviating mammalian obesity
|
|
WO2000069445A1
(en)
|
1999-05-13 |
2000-11-23 |
Geltex Pharmaceuticals, Inc. |
Combination therapy for treating hypercholesterolemia
|
|
AU773385B2
(en)
|
1999-05-14 |
2004-05-27 |
Esperion Luv Development, Inc. |
Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
|
|
WO2000072829A1
(en)
|
1999-05-28 |
2000-12-07 |
Abbott Laboratories |
Novel formulations comprising lipid-regulating agents
|
|
US6465011B2
(en)
|
1999-05-29 |
2002-10-15 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
|
JP4618845B2
(ja)
|
1999-06-09 |
2011-01-26 |
杏林製薬株式会社 |
ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
|
|
US6372251B2
(en)
|
1999-06-11 |
2002-04-16 |
Abbott Laboratories |
Formulations comprising lipid-regulating agents
|
|
GB9913782D0
(en)
|
1999-06-14 |
1999-08-11 |
Smithkline Beecham Plc |
Novel compounds
|
|
US6399640B1
(en)
|
1999-06-18 |
2002-06-04 |
Merck & Co., Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
|
AU770870B2
(en)
|
1999-06-18 |
2004-03-04 |
Merck & Co., Inc. |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
|
US6207699B1
(en)
|
1999-06-18 |
2001-03-27 |
Richard Brian Rothman |
Pharmaceutical combinations for treating obesity and food craving
|
|
GB9914977D0
(en)
|
1999-06-25 |
1999-08-25 |
Glaxo Group Ltd |
Chemical compounds
|
|
ES2437103T3
(es)
|
1999-06-30 |
2014-01-08 |
Amgen Inc. |
Compuestos para la modulacion de la actividad de PPAR gamma
|
|
EP1200091B1
(en)
|
1999-08-03 |
2008-07-02 |
Lilly Icos LLC |
Pharmaceutical composition comprising tadalafil
|
|
EP1078632A1
(en)
|
1999-08-16 |
2001-02-28 |
Sanofi-Synthelabo |
Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
|
|
GB9919413D0
(en)
|
1999-08-18 |
1999-10-20 |
Zeneca Ltd |
Chemical compounds
|
|
GB9919411D0
(en)
|
1999-08-18 |
1999-10-20 |
Zeneca Ltd |
Chemical compounds
|
|
US6734199B1
(en)
|
1999-08-23 |
2004-05-11 |
Kyorin Pharmaceutical Co., Ltd. |
Substituted benzylthiazolidine-2, 4-dione derivatives
|
|
DE60020381T2
(de)
|
1999-08-23 |
2006-01-26 |
Kyorin Pharmaceutical Co., Ltd. |
Substituierte benzylthiazolidin-2,4-dion-derivate
|
|
CN1152025C
(zh)
|
1999-08-23 |
2004-06-02 |
杏林制药株式会社 |
取代的苄基噻唑烷-2,4-二酮衍生物
|
|
AU7073400A
(en)
|
1999-08-27 |
2001-03-26 |
Eli Lilly And Company |
Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
|
|
AU782386C
(en)
|
1999-08-31 |
2006-08-10 |
Brigham And Women's Hospital |
Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
|
|
ES2215719T3
(es)
|
1999-09-08 |
2004-10-16 |
Glaxo Group Limited |
Antagonista ppar oxazol.
|
|
DE60028054T2
(de)
|
1999-09-08 |
2006-12-21 |
Genentech, Inc., South San Francisco |
Fibroblasten-wachstumsfaktor-19 (fgf-19) nukleinsäure und polypeptide und verfahren zu deren verwendung für behandlung von fettleibigkeit
|
|
US6174665B1
(en)
|
1999-09-10 |
2001-01-16 |
Biex, Inc. |
Hormone replacement therapy monitoring
|
|
DE60025621T2
(de)
|
1999-09-17 |
2006-11-23 |
Kyorin Pharmaceutical Co., Ltd. |
O-anisamid-derivate
|
|
US6376242B1
(en)
|
1999-09-21 |
2002-04-23 |
Emory University |
Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
|
|
CA2388417A1
(en)
|
1999-09-22 |
2001-03-29 |
Genset |
Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
|
|
AU5759499A
(en)
|
1999-09-24 |
2001-04-24 |
Kyorin Pharmaceutical Co. Ltd. |
Pparalpha and ppargamma inhibitors
|
|
AU2833701A
(en)
|
1999-09-30 |
2001-05-10 |
Shell Internationale Research Maatschappij B.V. |
Adducts of glycidylesters of alpha, alpha-branched carboxylic acids and carboxylic acids and poly(ortho ester) as intermediate for their preparation
|
|
AU7717500A
(en)
|
1999-09-30 |
2001-04-30 |
Merck & Co., Inc. |
Anti-hypercholesterolemic drug combination
|
|
AU7995300A
(en)
|
1999-10-05 |
2001-05-10 |
Bethesda Pharmaceuticals, Inc. |
Dithiolane derivatives
|
|
EP1284728A4
(en)
|
1999-10-22 |
2004-05-19 |
Merck & Co Inc |
MEDICINES FOR TREATING ADDICTIC ADDICTION
|
|
AU780624B2
(en)
|
1999-11-04 |
2005-04-07 |
Andrx Corporation |
Method of treating amyloid beta precursor disorders
|
|
AU1304601A
(en)
|
1999-11-11 |
2001-06-06 |
Kyorin Pharmaceutical Co. Ltd. |
Solid preparations for oral use
|
|
CA2388807C
(en)
|
1999-11-12 |
2013-08-06 |
Matthew C. Coffey |
Viruses for the treatment of cellular proliferative disorders
|
|
HUP0203431A3
(en)
|
1999-12-03 |
2003-11-28 |
Kyoto Pharma Ind |
Novel heterocyclic compounds and salts thereof and pharmaceutical compositions containing and use of the same
|
|
ATE293977T1
(de)
|
1999-12-08 |
2005-05-15 |
Pharmacia Corp |
Nanopartikelzusammensetzungen enthaltend eplerenon
|
|
SK287105B6
(sk)
|
1999-12-20 |
2009-12-07 |
Schering Corporation |
Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
|
|
US6248359B1
(en)
|
2000-01-05 |
2001-06-19 |
Laboratorios Phoenix U.S.A., Inc. |
Multi-tablet oxybutynin system for treating incontinence
|
|
US20010028895A1
(en)
|
2000-02-04 |
2001-10-11 |
Bisgaier Charles L. |
Methods of treating alzheimer's disease
|
|
CA2400021A1
(en)
|
2000-02-18 |
2001-08-23 |
Merck & Co., Inc. |
Aryloxyacetic acids for diabetes and lipid disorders
|
|
HRP20020649A2
(en)
|
2000-02-29 |
2004-12-31 |
Bristol Myers Squibb Co |
Low dose entecavir formulation and use
|
|
EP1272220B2
(en)
|
2000-04-10 |
2016-07-27 |
Nicholas John Wald |
Formulation for the prevention of cardiovascular disease
|
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
|
US20020013334A1
(en)
|
2000-06-15 |
2002-01-31 |
Robl Jeffrey A. |
HMG-CoA reductase inhibitors and method
|
|
US6191117B1
(en)
|
2000-07-10 |
2001-02-20 |
Walter E. Kozachuk |
Methods of producing weight loss and treatment of obesity
|
|
AU7705601A
(en)
|
2000-07-25 |
2002-02-05 |
Merck & Co Inc |
N-substituted indoles useful in the treatment of diabetes
|
|
US20020132855A1
(en)
|
2000-08-03 |
2002-09-19 |
Nelson Edward B. |
Use of acetaminophen to prevent and treat arteriosclerosis
|
|
DE10042447A1
(de)
|
2000-08-29 |
2002-03-28 |
Aventis Pharma Gmbh |
Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
|
|
JP2004513090A
(ja)
|
2000-09-27 |
2004-04-30 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
|
|
ATE369334T1
(de)
|
2000-12-20 |
2007-08-15 |
Schering Corp |
Hydroxysubstituierte 2-azetidinone verwendbar als hypocholesterolemische arzneimittel
|
|
BR0116325A
(pt)
|
2000-12-21 |
2003-10-14 |
Aventis Pharma Gmbh |
1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
|
|
ATE338039T1
(de)
|
2000-12-21 |
2006-09-15 |
Sanofi Aventis Deutschland |
Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
IL156552A0
(en)
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
|
US20020147184A1
(en)
|
2001-01-26 |
2002-10-10 |
Schering Corporation |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
|
CN1582168A
(zh)
|
2001-01-26 |
2005-02-16 |
先灵公司 |
用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合
|
|
RS20100015A
(sr)
|
2001-01-26 |
2010-12-31 |
Schering Corporation |
Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
|
|
HU230435B1
(hu)
*
|
2001-01-26 |
2016-06-28 |
Merck Sharp & Dohme Corp |
Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
|
|
SI1363668T1
(sl)
|
2001-01-26 |
2007-12-31 |
Schering Corp |
Kombinacija sekvestranta(-ov) in zaviralca(-ev) absorpcije sterola ter zdravljenje vaskularnih indikacij
|
|
AU2002240050A1
(en)
|
2001-01-26 |
2002-08-06 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
AU2002251978B2
(en)
|
2001-02-09 |
2007-07-19 |
Merck & Co., Inc. |
2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
|
|
DE10106787A1
(de)
|
2001-02-12 |
2002-08-22 |
Nanogate Gmbh |
Wasserfrei hydrolisierte Sol-Gel-Systeme
|
|
BR0207227A
(pt)
|
2001-02-15 |
2004-02-10 |
Pfizer Prod Inc |
Compostos receptores ativados proliferadores ppar
|
|
WO2002064549A1
(en)
|
2001-02-15 |
2002-08-22 |
Pfizer Products Inc. |
Ppar agonists
|
|
EP1389114A2
(en)
|
2001-03-08 |
2004-02-18 |
Merck & Co., Inc. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
|
WO2002081454A1
(en)
|
2001-04-09 |
2002-10-17 |
Dr. Reddy's Laboratories Ltd. |
Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
|
|
NZ531292A
(en)
|
2001-08-22 |
2005-08-26 |
Aventis Pharma Gmbh |
Combination products of aryl-subsituted propanolamine derivatives with other active ingredients and the use thereof
|
|
JP2005501861A
(ja)
|
2001-08-22 |
2005-01-20 |
アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
１，４−ベンゾチエピン１，１−ジオキシド誘導体と他の活性物質との組合わせ剤及びそれらの使用
|
|
WO2003039542A1
(en)
|
2001-10-17 |
2003-05-15 |
Merck & Co. Inc. |
Combination therapy for treating alzheimer's disease
|
|
AU2003217276A1
(en)
|
2002-02-28 |
2003-09-16 |
Eli Lilly And Company |
Method of treating atherosclerosis and hypercholesterolemia
|
|
AU2003225027A1
(en)
|
2002-04-16 |
2003-11-03 |
Merck And Co., Inc. |
Combination therapy using a ppar alpha/gamma agonist
|